Given that previous studies have observed complementary activity of PD-L1 and CTLA-4 blockade (Bowyer et al., 2016; Wolchok et al., 2017, 2022), it is possible that the concentration of ICIs or the dosing regimen we used was not optimal for blockade of both PD-L1 and CTLA-4 in these tumor models, thus further studies are required. This evidence concerns the gene CTLA4 and neoplasm.